Real-world data of triplet combination of pyrotinib, trastuzumab, and chemotherapy in HER2-positive metastatic breast cancer: a multicenter, retrospective study.

Ther Adv Med Oncol · 2023 · PMC10748899 · PMID 38145113

Europe PMC DOI

hedged sentences

0.0230

closest p · 0.5× alpha

0.0590

boldest claim

The sentences

showed a trendp = 0.023actually significant

Interestingly, prior trastuzumab exposure did not significantly affect median PFS [12.57 versus 8.05 months, p = 0.541, Figure 5(a) ], yet a longer duration (⩾6.37 months) showed a trend toward improved PFS [12.02 versus 5.32 months, p = 0.023, Figure 5(b) ].

also in 18,965 other papers

approached significancep = 0.059so close (0.05 < p ≤ 0.1)

The lines of advanced systematic therapy of PyroHC (1–2 versus ⩾3) approached significance with an HR of 0.673 (95% CI: 0.447–1.015, p = 0.059).

also in 2,355 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.